Madrigal Pharmaceuticals (MDGL) Earnings Date, Estimates & Call Transcripts $333.91 -6.89 (-2.02%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Madrigal Pharmaceuticals Earnings Summary Upcoming Earnings DateMay. 1Before Market OpensEstimatedConsensus EPS (Feb. 26) -$4.32 Actual EPS (Feb. 26) -$2.71 Beat By $1.61 Actual Revenue (Feb. 26) $103.32MMadrigal Pharmaceuticals released Q4 2024 earnings on February 26, 2025, reporting an EPS of -$2.71, which topped the consensus estimate of -$4.32 by $1.61. Quarterly revenue was reported to be $103.32 million, above analysts' expectations of $97.81 million. With a trailing EPS of -$22.11, Madrigal Pharmaceuticals' earnings are expected to grow next year, from ($23.47) to ($12.00) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportConference Call Transcript & Audio Annual Report (10-K) Press Release (8-K)MDGL Upcoming EarningsMadrigal Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get Madrigal Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataMDGL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MDGL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Madrigal Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$2.83-$2.71-$2.77Q2 20253-$2.59-$1.83-$2.19Q3 20253-$1.81-$1.20-$1.55Q4 20253-$1.23-$0.32-$0.79FY 202511($8.46)($6.06)($7.30) Madrigal Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/1/2025(Estimated)-------2/26/2025Q4 2024-$4.32-$2.71+$1.61-$2.71$97.81M$103.32M10/31/2024Q3 2024-$6.94-$4.92+$2.02-$4.92$34.60M$62.18M8/7/2024Q2 2024-$7.55-$7.10+$0.45-$7.10$4.25M$14.64M5/7/2024Q1 2024-$6.06-$7.38 -$1.32-$7.38--2/28/2024Q4 2023-$5.26-$5.68 -$0.42-$5.68--11/6/2023Q3 2023-$4.90-$5.34 -$0.44-$5.34--8/8/2023Q2 2023-$4.59-$4.69 -$0.10-$4.69--5/9/2023Q1 2023-$4.78-$4.23+$0.55-$4.23-- Madrigal Pharmaceuticals Earnings - Frequently Asked Questions When is Madrigal Pharmaceuticals's earnings date? Madrigal Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 1st, 2025 based off last year's report dates. Learn more on MDGL's earnings history. Did Madrigal Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Madrigal Pharmaceuticals (NASDAQ:MDGL) reported ($2.71) earnings per share (EPS) to beat the analysts' consensus estimate of ($4.32) by $1.61. Learn more on analysts' earnings estimate vs. MDGL's actual earnings. How can I listen to Madrigal Pharmaceuticals's earnings conference call? The conference call for Madrigal Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Madrigal Pharmaceuticals's conference call transcript? The conference call transcript for Madrigal Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Madrigal Pharmaceuticals generate each year? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded annual revenue of $180.13 million. How much profit does Madrigal Pharmaceuticals generate each year? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a recorded net income of -$373.63 million. MDGL has generated -$22.11 earnings per share over the last four quarters. What is Madrigal Pharmaceuticals's EPS forecast for next year? Madrigal Pharmaceuticals's earnings are expected to grow from ($23.47) per share to ($12.00) per share in the next year. More Earnings Resources from MarketBeat Related Companies BIIB Earnings Date UTHR Earnings Date BMRN Earnings Date INCY Earnings Date EXEL Earnings Date NBIX Earnings Date EXAS Earnings Date RGEN Earnings Date HALO Earnings Date IONS Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of Earnings This page (NASDAQ:MDGL) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.